Castle Biosciences has signed an agreement to acquire GI health company Previse, which was developed by specialists at Johns Hopkins University School of Medicine in Baltimore.
Previse is focused on chronic acid reflux related diseases, including esophageal cancer, according to a May 5 news release from Castle Biosciences.
Terms of the agreement have not been disclosed. Through the acquisition, Castle will expand its GI vertical, which currently includes the TissueCypher Barrett’s Esophagus test.
Previse was established in 2018 and developed by Stephen Meltzer, MD, and the GI Early Detection Biomarker Lab at Johns Hopkins.
The technology, specifically Previse’s Esopredict, an epigenetic test designed to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with precancerous Barrett’s esophagus, is backed by funding from the National Institutes of Health.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.